Thyroid-associated ophthalmopathy: linear regression analysis of single photon emission computed tomography

1. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al. Interpretation and validity of changes in scores on the Graves’ ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001; 54:391-8.10.1046/j.1365-2265.2001.01241.x11298093Open DOISearch in Google Scholar

2. Wall JR and Lahooti H. Pathogenesis of thyroid eye disease-does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol. 2010; 61:222-7.Search in Google Scholar

3. Lahooti H, Parmar KR, and Wall JR. Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role? Clin Ophthalmol. 2010; 4:417-25.Search in Google Scholar

4. Dittmar M and Kahaly GJ. Immunoregulatory and susceptibility genes in thyroid and polyglandular autoimmunity. Thyroid. 2005; 15:239-50.10.1089/thy.2005.15.23915785243Open DOISearch in Google Scholar

5. Weetman AP. Graves’ disease. N Engl J Med. 2000; 343:1236-48.10.1056/NEJM20001026343170711071676Open DOISearch in Google Scholar

6. Pappa A, Lawson JM, Calder V, Fells P, and Lightman S. T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy. Br J Ophthalmol. 2000; 84:517-22.10.1136/bjo.84.5.517172344910781517Open DOISearch in Google Scholar

7. Chavis PS. Thyroid and the eye. Curr Opin Ophthalmol. 2002; 13:352-6.10.1097/00055735-200212000-0000212441836Open DOISearch in Google Scholar

8. Krassas GE. Octreoscan in thyroid-associated ophthalmopathy. Thyroid. 2002; 12:229-31.10.1089/10507250275360018811952044Open DOISearch in Google Scholar

9. Galuska L, Varga J, Farkas ZS, Garai I, Boda J, Szabo J, et al. Active retrobulbar inflammation in Graves’ ophthalmopathy visualized by Tc-99m DTPA SPECT. Clin Nucl Med. 2003; 28:515-6.10.1097/01.RLU.0000067520.87766.B612917542Open DOISearch in Google Scholar

10. Galuska L, Leovey A, Szucs-Farkas Z, Szabados L, Garai I, Berta A, et al. Imaging of disease activity in Graves’ orbitopathy with different methods: comparison of 99mTc-DTPA and 99mTc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl Med Commun. 2005; 26:407-14.10.1097/00006231-200505000-0000315838422Open DOISearch in Google Scholar

11. Galuska L, Leovey A, Szucs-Farkas Z, Garai I, Szabo J, Varga J, et al. SPECT using 99mTc-DTPA for the assessment of disease activity in Graves’ ophthalmopathy: a comparison with the results from MRI. Nucl Med Commun. 2002; 23:1211-6.10.1097/00006231-200212000-0001012464787Open DOISearch in Google Scholar

12. Forster GJ, Krummenauer F, Nickel O, and Kahaly GJ. Somatostatin-receptor scintigraphy in Graves’ disease: reproducibility and variance of orbital activity. Cancer Biother Radiopharm. 2000; 15:517-25.10.1089/cbr.2000.15.51711155823Open DOISearch in Google Scholar

13. Burggasser G, Hurtl I, Hauff W, Lukas J, Greifeneder M, Heydari B, et al. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves’ disease. J Nucl Med. 2003; 44:1547-55.Search in Google Scholar

14. Sun H, Jiang XF, Wang S, Chen HY, Sun J, Li PY, et al. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves’ ophthalmopathy (GO). Endocrine. 2007; 31:305-10.10.1007/s12020-007-0039-217906380Open DOISearch in Google Scholar

15. Kirsch E, von Arx G, and Hammer B. Imaging in Graves’ orbitopathy. Orbit. 2009; 28:219-25. Search in Google Scholar